Co-overexpression of p21 and Ki-67 in head and neck squamous cell carcinoma relative to a significantly poor prognosis

Head Neck. 2011 Feb;33(2):267-73. doi: 10.1002/hed.21440.

Abstract

Background: Head and neck squamous cell carcinomas (HNSCC) are treated by surgery or radiotherapy. Tumor cell death-related markers, such as p21 and Ki-67, may predict response to therapy and improve treatment choice. We evaluated and compared the effect of their coexpression between patients treated by surgery or radiotherapy.

Methods: Immunohistochemistry for p21 and Ki-67 expression in 144 pharyngeal and laryngeal HNSCC samples was analyzed and correlated with follow-up parameters.

Results: p21 expression correlated significantly with positive cN classification (p < .001), locoregional relapse (p = .031), and poor overall survival (p = .016), and Ki-67 positivity with poor survival only (p = .025). Coexpressing tumor phenotypes showed the worst survival (p = .009), observed primarily in patients treated by radiotherapy (p = .077).

Conclusions: Coexpression of p21/Ki-67 is a strong negative prognostic factor in HNSCC and could be of particular relevance in tumors treated by primary radiotherapy.

Publication types

  • Comparative Study

MeSH terms

  • Biomarkers, Tumor / biosynthesis
  • Biopsy
  • Carcinoma, Squamous Cell / enzymology
  • Carcinoma, Squamous Cell / metabolism*
  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / pathology*
  • Carcinoma, Squamous Cell / therapy
  • Cyclin-Dependent Kinase Inhibitor p21 / biosynthesis*
  • Female
  • Gene Expression Regulation, Neoplastic
  • Head and Neck Neoplasms / enzymology
  • Head and Neck Neoplasms / metabolism*
  • Head and Neck Neoplasms / mortality
  • Head and Neck Neoplasms / pathology*
  • Head and Neck Neoplasms / therapy
  • Humans
  • Immunohistochemistry
  • Ki-67 Antigen / biosynthesis*
  • Male
  • Predictive Value of Tests
  • Prognosis
  • Protein Kinase Inhibitors / metabolism*
  • Retrospective Studies
  • Sensitivity and Specificity
  • Severity of Illness Index
  • Survival Analysis
  • Up-Regulation

Substances

  • Biomarkers, Tumor
  • Cyclin-Dependent Kinase Inhibitor p21
  • Ki-67 Antigen
  • Protein Kinase Inhibitors